Defence Therapeutics Collaboration Agreement With Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer Advances

newsfileAug 13 03:15 ET

Defence Receives No Objection Letter From Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients With Melanoma

newsfileJul 8 03:15 ET

Defence's AccuTOX Boosts and Synergizes With Immune Checkpoint Inhibitors

newsfileJun 28 17:08 ET

Defence's ARM-X Anti-Cancer Vaccine Inhibits Growth of Pre-Established Ovarian Cancer Resulting in Complete Responses in Treated Animals

newsfileJun 25 03:15 ET

Defence's Chief Scientific Officer Dr. Moutih Rafei Discusses the Accum Platform for Cancer Treatments on Money Talk Radio With Ellis Martin

newsfileJun 17 03:15 ET

Defence to Participate in 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024

newsfileJun 10 03:15 ET